- Company
- HAE treatment 'Takhzyro' closer to reimbursement
- by Eo, Yun-Ho Nov 10, 2025 06:08am
- A hereditary angioedema (HAE) treatment, 'Takhzyro,' appears closer to insurance reimbursement listing, approximately five years after acquiring domestic approval in South Korea. Takeda Korea's Takhzyro (lanadelumab) has recently passed the Drug Reimbursement Evaluation Committee (DREC). This is the first achievement since receiving appro
- Company
- GSK seeks reimb for self-injectable form of its asthma drug
- by Eo, Yun-Ho Nov 7, 2025 06:17am
- The self-injectable formulation of the antibody drug ‘Nucala’ is aiming to enter Korea’s insurance reimbursement system. GSK Korea recently filed for insurance reimbursement of its Nucala Autoinjector (mepolizumab), an anti-IL-5 (interleukin-5) antibody for treating eosinophilic diseases. Nucala Autoinjector was approved in Korea la
- Company
- "Rise of regenerative aesthetics focused on natural beauty"
- by Hwang, byoung woo Nov 7, 2025 06:17am
- As the use of medical aesthetics treatments expands, the field is moving away from excessive volume correction toward a focus on natural balance and improved skin quality. As the proportion of surgical procedures decreases, minimally invasive procedures are expanding, and a strategy focused on maintaining long-term safety and efficacy is beco
- Company
- 31 Chinese, 2 Korean firms rank among the global Top 100
- by Kim, Jin-Gu Nov 7, 2025 06:16am
- Two Korean companies made it into the Top 100 global pharmaceutical and biotech firms by revenue. Samsung Biologics and Celltrion ranked 64th and 87th, respectively. By nationality, Chinese and Hong Kong-based companies led with 31 firms, followed by the US (23), Japan (12), and India (6). According to data released on the 6th by BullFinch
- Company
- Samsung Biologics spins off Samsung Epis Holdings
- by Cha, Jihyun Nov 6, 2025 06:34am
- Samsung Biologics spun off its investment and subsidiary management business unit to establish Samsung Epis Holdings as a dedicated bio investment holding company The company announced on the 3rd that the holding company was officially established following a board resolution. Samsung Bioepis Holdings will establish separate subsidiaries
- Company
- GSK reattempts reimb for myelofibrosis drug Omjjara
- by Eo, Yun-Ho Nov 6, 2025 06:33am
- GSK’s myelofibrosis drug Omjjara (momelotinib), which failed reimbursement on its first attempt, is once again seeking insurance reimbursement in Korea. According to industry sources, GSK Korea recently resubmitted its reimbursement application for Omjjara. Despite its recent failure to be presented to the Health Insurance Review and Ass
- Company
- "Fosamax's value in osteoporosis sequential therapy rises"
- by Hwang, byoung woo Nov 6, 2025 06:32am
- As South Korea enters a super-aged society, the importance of long-term management in osteoporosis treatment is being emphasized. During this process, the bisphosphonate class of drugs, demonstrating long-term evidence and sustained efficacy, is once again becoming the key treatment strategy. DailyPharm met with Professor Beom-jun Kim of t
- Company
- "Bavencio MT after short chemotherapy proves survival·QoL"
- by Hwang, byoung woo Nov 6, 2025 06:30am
- The treatment for urothelial carcinoma is shifting toward the direction of 'short chemotherapy, long survival'. The DISCUS study confirmed that there is no difference in treatment outcome even when platinum-based chemotherapy is administered for only three cycles. This evidence demonstrated that it can reduce unnecessary toxicity while maint
- Company
- 'Leqembi will reshape early dementia care landscape'
- by Hwang, byoung woo Nov 5, 2025 06:23am
- Leqembi (lecanemab), a therapy that directly removes the pathogenic protein driving Alzheimer's disease and slows disease progression, is opening a new treatment paradigm in a super-aged society. Unlike existing drugs that primarily focused on symptomatic relief, Leqembi has demonstrated disease-modifying potential, signaling broad changes ac
- Company
- Alfresa launches Jenecell to expand stem-cell business in KR
- by Chon, Seung-Hyun Nov 5, 2025 06:22am
- Alfresa Group, a major Japanese pharmaceutical distribution company, has entered the Korean market with the establishment of its subsidiary Jenecell and declared its entry into the stem cell business market. Alfresa Corporation announced on the 3rd that it has established Jenecell in Korea. The Alfresa Group is a Japanese healthcare compa
